AssetMark Inc’s Definium Therapeutics DFTX Stock Holding History

AssetMark Inc’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-8	Closed	-$29	–	1786
2023 Q2	$29	Buy	+8	New	+$28	﹤0.01%	1549

Other funds holding DFTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

AssetMark Inc's DFTX Position: Q3 2023 in Review

AssetMark Inc sold out of Definium Therapeutics (DFTX) in Q3 2023, closing a stake of 8 shares — an estimated $29 sold.

AssetMark Inc first reported a position in DFTX in Q2 2023 and held it in 1 quarter. The position peaked at $29 in Q2 2023. 93 funds tracked by Wall St. Rank hold DFTX as of Q3 2023.

AssetMark Inc reported no remaining Definium Therapeutics position as of Q3 2023 after selling out during the quarter.
AssetMark Inc sold 8 Definium Therapeutics shares in Q3 2023, an estimated $29.
AssetMark Inc first reported a position in Definium Therapeutics in Q2 2023 and held it in 1 quarter.
AssetMark Inc's Definium Therapeutics position peaked at $29 in Q2 2023.
93 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2023.

Based on AssetMark Inc's 13F filing for Q3 2023, filed 27 Oct 2023.